1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice

The administration to mice of 1-methyl-4-(2'-methylphenyl)-1,2,3, 6-tetrahydropyridine (2'-CH3-MPTP), a substituted analog of the dopaminergic neurotoxin MPTP caused even more dopaminergic toxicity than MPTP itself. Under conditions in which MPTP was relatively ineffective (i.e. two injections per day of 0.113 mmol/kg at an interval of 6 h for one or two days), 2'-CH3-MPTP caused a very large decrement in the neostriatal content of dopamine and its metabolites and a corresponding decrement in the capacity of a neostriatal synaptosomal preparation to take up [3H]dopamine. Moreover, 2'-CH3-MPTP administration (as few as four injections) caused a virtually complete loss of nerve cells in the zona compacta of the substantia nigra. This compound, like MPTP, may prove to be a valuable research tool.     

Adaptation française du Patient Generated Index: qualités métrologiques et limites pratiques

The aims of this research are to (1) present the French version of the Patient Generated Index (PGI, [17]), (2) test its psychometric characteristics and (3) examine the tool’s practical limitations. To achieve those goals, we conducted two studies. The first was a qualitative study of 18 participants who indicated their difficulties and expressed other comments concerning the completion of an initial back translation of the PGI. The second study tested the psychometric qualities of the adapted and revised back translation of the PGI with 97 cancer patients. To assess criterion validity, they also completed the Quality of Life Questionnaire C30 (QLQ-C30), Profile of Mood States (POMS) and Satisfaction With Life Scale (SWLS). The results indicate that PGI has good sensitivity, validity and test-retest stability. Test-retest reliability, nevertheless, must be improved.     

Clinical and molecular findings in IPEX syndrome.

IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X linked syndrome) is a rare disorder which usually results in death in early infancy or childhood. Clinical awareness remains the cornerstone of diagnosis, and provided that the diagnosis is entertained, mutation analysis for FOXP3 gene mutations can be confirmatory. Two new patients in whom IPEX was diagnosed retrospectively are reported.